Targeted drug delivery of Rifampicin to the lungs: Formulation, characterization, and stability studies of preformed aerosolized liposome and in situ formed aerosolized liposome

Drug Development and Industrial Pharmacy

Volumn 36, Issue 6, 2010, Pages 638-646

  Gaur, Praveen Kumar ^a   Mishra, Shikha ^a   Gupta, Vipin Bihari ^b   Rathod, Mahendra Singh ^b   Purohit, Suresh ^c   Savla, Bhavin A ^d  

^a ITS Paramedical College Pharmacy   (India)

^b B R NAHATA COLLEGE OF PHARMACY   (India)

^c Marwar Pharmacy College   (India)

^d R and D Section   (India)

Author keywords

Aerosol; Alveoli; In situ; Liposome; Rifampicin; Tuberculosis

Indexed keywords

CHLOROFLUOROCARBON; LIPOSOME; RIFAMPICIN;

AEROSOL; ARTICLE; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG RELEASE; DRUG STABILITY; ENCAPSULATION; FEASIBILITY STUDY; HYDRATION; KINETICS; LUNG; MEMBRANE VESICLE; SIMULATION; TUBERCULOSIS;

AEROSOLS; ANIMALS; CHEMISTRY, PHARMACEUTICAL; DRUG DELIVERY SYSTEMS; DRUG STABILITY; LIPOSOMES; LUNG; RATS; RIFAMPIN;

EID: 77952517959     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.3109/03639040903410300     Document Type: Article

References (47)

1. Russell DG. (2001). Mycobacterium tuberculosis: Here today, and here tomorrow. Nat Rev Mol Cell Biol, 2:569-77.
2. Tasdug SA, Peerzada K, Koul S, Bhat R, Johri RK. (2005). Biochemical manifestations of anti-tuberculosis drugs induced hepatotoxicity and the effect of silymarin. Hepatol Res, 31:132-5.
3. Justesen US, Andersen AB, Klitgaard NA, Brosen K, Gerstoft J, Pedersen C. (2004). Pharmacokinetic interaction between rifampin and the combination of indinavir and low-dose ritonavir in HIV-infected patients. Clin Infect Dis, 38:426-9.
4. Shishoo CJ, Shah SA, Rathod IS, Savale SS, Kotecha JS, Shah PB. (1999). Stability of Rifampicin in dissolution medium in presence of isoniazid. Int J Pharm, 190:109-23.
5. Niemi M, Backman JT, Fromm MF, Neuvonen PJ, Kivisto KT. (2003). Pharmacokinetic interactions with Rifampicin: Clinical relevance. Clin Pharmacokinet, 42:819-50.
6. Purohit SD, Gupta ML, Meena RC, Jatn DK, Sarkar SK, Gupta PR. (1989). Rifampicin aerosol administration in Guinea-Pigs (an experimental study). Indian J Pharmacol, 21:100-3.
7. Saito H, Tomioka H. (1989). Therapeutic efficacy of liposomeentrapped Rifampin against mycobacterium avium complex infection induced in mice. Antimicrob Agents Chemother, 33 (4):429-33.
8. Deol P, Khuller GK, Joshi K. (1997). Therapeutic efficacies of isoniazid and Rifampin encapsulated in lung-specific stealth liposomes against mycobacterium tuberculosis infection induced in mice. Antimicrob Agents Chemother, 41 (6):1211-4.
9. Deol P, Khuller GK. (1997). Lung specific stealth liposomes: Stability, biodistribution and toxicity of liposomal antitubercular drugs in mice. Biochim Biophys Acta, 1334:161-72.
10. Bermúdez M, Martinez E, Mora M, Sagristá ML, de Madariaga MA. (1999). Molecular and physicochemical aspects of the interactions of the tuberculostatics ofloxacin and rifampicin with liposomal bilayers: A 31P-NMR and DSC study. Colloids Surf, 158:59-66.
11. Labana S, Pandey R, Sharma S, Khuller GK. (2002). Chemotherapeutic activity against murine tuberculosis of once weekly administered drugs (isoniazid and rifampicin) encapsulated in liposomes. Int J Antimicrob Agents, 20:301-4.
12. Rodrigues C, Gameiro P, Prieto M, De Castro B. (2003). Interaction of rifampicin and isoniazid with large unilamellar liposomes: Spectroscopic location studies. Biochim Biophys Acta, 1620:151-9.
13. Vyas SP, Khanna ME, Jain S, Mishra V, Singh P. (2004). Design of liposomal aerosols for improved delivery of Rifampicin to alveolar macrophages. Int J Pharm, 269:37.
14. Gürsoy A, Kut E, Özkirimli S. (2004). Co-encapsulation of isoniazid and rifampicin in liposomes and characterization of liposomes by derivative spectroscopy. Int J Pharm, 271:115-23.
15. Zaru M, Mourtas S, Klepetsanis P, Fadda AM, Antimisiaris SG. (2007). Liposomes for drug delivery to the lungs by nebulization. Eur J Pharm Biopharm, 67:655-66.
16. Sorokoumova GM, Vostrikov VV, Selishcheva AA, Rogozhkina EA, Kalashnikova TYu, Shvets VI, et al. (2008). Bacteriostatic activity and decomposition products of Rifampicin in aqueous solution and liposomal composition. Pharm Chem J, 42 (8):475-8.
17. Changsan N, Chan H-K, Separovic F, Srichana T. (2009). Physicochemical characterization and stability of Rifampicin liposome dry powder formulations for inhalation. J Pharm Sci, 98 (2):628-39.
18. Dhand R. (2000). Special problems in aerosol delivery: Artificial airways. Respir Care, 45:636.
19. Bhavane R, Karathanasis E, Annapragada AV. (2003). Agglomerated vesicle technology: A new class of particles for controlled and modulated pulmonary drug delivery. J Control Release, 93:15.
20. Farr SJ, Kellaway IW, Carman-Meaking B. (1987). Assessing the potential of aerosol generated liposomes from pressurized pack formulations. Design of liposomal aerosols for improved delivery of Rifampicin to alveolar macrophages. J Control Release, 5:119.
21. Leach CL. (1995). Approaches and challenges to use freon propellant replacements. Aerosol Sci Technol, 22:328.
22. Newman SP. (2005). Principles of metered-dose inhaler design. Respir Care, 50:1177.
23. Butz N, Porté C, Courrier H, Krafft MP, Vandamme ThF. (2002). Reverse water-in-fluorocarbon emulsions for use in pressurized metered-dose inhalers containing hydrofluoroalkane propellants. Int J Pharm, 238:257.
24. Borgström L. (1999). The pharmacokinetics of inhaled hydroflouroalkane formulations. J Allergy Clin Immunol, 104: S246-9.
25. Burkhard WV, Ricardo BMW, Schreier H. (1992). Amikacin liposomes characterization, aerosolization, and in vitro activity against Mycobacterium avium-intracellular in alveolar macrophages. Int J Pharm, 78:227.
26. Tabake A, Hoffer E, Taitelman U. (1994). Evaluation of a liposome system for the delivery of desferrioxamine to lungs in rats. J Pharm Pharmacol, 46:786.
27. Fraser DS, Yong PM, Price R, Edge TS, Lewis D. (2004). The potential use of Raman mapping to investigate in vitro deposition of combination pressurized metered dose inhalers. AAPS J, 6:1.
28. Farr SJ, Kellaway IW, Parry Jones DR, Woolfrey SG. (1985). 99m-Technetium as a marker of liposome disposition and clearance in the human lung. Int J Pharm, 26:303.
29. Farr SJ. (1989). Comparison of solute partitioning and efflux in liposomes formed by a preformed and an aerosolised method. Int J Pharm, 51:39.
30. Fauroux B, Itti E, Pigeot J. (2000). Optimization of aerosol deposition by pressure support in children with cystic fibrosis. Am J Respir Crit Care Med, 162:2265.
31. Schreir H, McNicol KJ, Ausborn M, Soucy DM, Derendorf H, Stecenko AA, et al. (1992). The pulmonary delivery of amikacin liposome's and acute liposome's toxicity in the sheep. Int J Pharm, 87:183.
32. Fideler IJ, Raz A, Krish R, Poste G. (1980). Design of liposomes to improve delivery of macrophage-augmenting agents to alveolar macrophages. Cancer Res, 40:4460.
33. Waldrep JC, Arppe J, Jansa KA, Knight V. (1997). High dose cyclosporine A and budesonide-liposome aerosols. Int J Pharm, 152:27.
34. Waldrep JC, Arppe J, Jansa KA, Vidgren M. (1998). Experimental pulmonary delivery of cyclosporine A by liposome aerosol. Int J Pharm, 160:239.
35. Hallworth GW, Westmoreland DG. (1987). The Twin impinger: A simple device for assessing the delivery of drugs from metered dose pressurized aerosol inhalers. J Pharm Pharmacol, 1987 (39):966.
36. Kirk WF. (1972). In vitro method of comparing clouds produced from inhalation aerosols for efficiency in penetration of airways. J Pharm Sci, 61:262.
37. Gupta VB. (1991). Lung targeting of cromolyn sodium using aerosolized liposome. M. Pharma thesis, Dept of Pharmaceutical Sciences, Dr. H. S. G. V, Sagar, M. P.
38. Sciarra JJ, Cutie AJ. (1987). Microencapsulation. In: Lachman L, Liberman A, Kanig JL, eds., The theory & practice of industrial pharmacy. Philadelphia: Lea & Febiger, 589-618.
39. Vyas SP, Khar RK. (2002). Targeted and controlled drug delivery: Novel carrier systems. New Delhi, India: Vallabh Prakashan.
40. Gunter KK, Gunter TE, Jarkowski A, Rosier RN. (1982). A method of resuspending small vesicles separated from suspensions by protamine aggregation and centrifugation. Anal Biochem, 120:113.
41. Byron PR, Roberts N. (1988). A novel dosing method for drug administration to the airways of the isolated perfused rat lung. J Pharm Sci, 77:693.
42. Feddah MR, Brown KF, Gipps EM. (2000). In-vitro characterization of metered dose inhaler versus dry powder inhaler glucocorticoid products: Influencing of inspiration flow rates. J Pharm Sci, 3:317.
43. Yammada K, Kamada N, Odomi M, Yamamoto A. (2005). Carrageenans can regulate the pulmonary absorption of anti-asthmatic drugs and their retention in the rat lung tissues with out any membrane damage. Int J Pharm, 293:63.
44. Kanaoka E, Hirano K. (1999). Stabilization of aerosolized inf-γ by liposomes. Int J Pharm, 188:165.
45. Kammy KM, Bridges PA, Taylor MG. (1996). The stability of liposome to ultrasonic nebulization. Int J Pharm, 145:96.
46. Taylor KMG, Taylor G, Kellaway IW, Stevens J. (1990). The stability of liposomes of liposomes to nebulization. Int J Pharm, 58:57.
47. Vyas SP, Quraishi S, Gupta S. (2005). Aerosolized liposomebased delivery of amphotericin B to alveolar macrophages. Int J Pharm, 296:12.